Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Exclusion Criteria

• •The patients in pregnancy or lactation growth period and did not take effective contraception;
• •The patients who received ≥4 chemotherapies after recurrence and metastasis; involved in other clinical trials four weeks prior to the start of the study;
• •The patients with a variety of factors that affect the oral administration and absorption of drugs;
• •Prior treatment with etoposide or antiangiogenic TKI (subjects with prior use of antiangiogenic macromolecules such as bevacizumab are allowed to be enrolled);
• •The patients have uncontrollable mental illness；
• •Serous cavity effusion (such as pleural effusion and ascites) with clinical symptoms requiring clinical intervention or stable time less than 4 weeks;
• •The patients who had serious adverse effect to oral etoposide or were allergic to etoposide.
• •The patients who have only bone metastasis without other measurable lesion;
• •The patients experience severe cardiovascular diseases;
• •The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.
• •Abnormal bone marrow functions(neutrophil\<1.5G/L, platelet count \<75G/L, hemoglobin \<90g/L);
• •Abnormal renal function(serum creatinine \> 1.5 times the upper limit of normal value);
• •Abnormal liver function(serum bilirubin ≤ 1.5 times the upper limit of normal value);
• •The patients have uncontrollable brain metastasis;
• •Active or uncontrolled infection requiring systematic treatment (except simple urinary tract infection or upper respiratory tract infection) during the 2 weeks or 2 weeks prior to enrollment;
• •Previous or concurrent history of other malignant tumors.Except for the cured skin basal cell carcinoma and cervical carcinoma in situ;
• •The patients do have good compliance to the therapy.